Primary prevention of coronary heart disease

Primary prevention of coronary heart disease refers to clinical management directed at individuals who have not yet developed clinically evident coronary artery disease or suffered a prior adverse cardiac event The cardiovascular system is affected, with pathology characterized by gradual atherogenesis—the buildup of fibrofatty, lipid-rich plaques within the coronary arterial walls that causes arterial narrowing, endothelial dysfunction, and vascular inflammation

The cardiovascular system is affected, with pathology characterized by gradual atherogenesis—the buildup of fibrofatty, lipid-rich plaques within the coronary arterial walls that causes arterial narrowing, endothelial dysfunction, and vascular inflammation This clinical state primarily targets populations with elevated cardiovascular risk profiles driven by modifiable or hereditary factors, such as dyslipidemia, hypertension, diabetes mellitus, or smoking The clinical focus is to attenuate plaqu...

The cardiovascular system is affected, with pathology characterized by gradual atherogenesis—the buildup of fibrofatty, lipid-rich plaques within the coronary arterial walls that causes arterial narrowing, endothelial dysfunction, and vascular inflammation The clinical focus is to attenuate plaque progression and prevent initial manifestations of ischemic heart disease, including stable angina, acute myocardial infarction, and sudden cardiac death

This clinical state primarily targets populations with elevated cardiovascular risk profiles driven by modifiable or hereditary factors, such as dyslipidemia, hypertension, diabetes mellitus, or smoking